Shattuck Labs Inc (STTK) Actualités

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a...

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a...

Shattuck Labs Announces Participation in Upcoming December Conferences

AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

 – Announced development of SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A; IND...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors